Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpoint
Question
Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpoint
Direct answer
Phase 3 clinical trial failures eliminate projected royalty cash flows and downstream drug commercialization revenue for licensing partners. — bearish pressure on RPRX via elimination of future pipeline royalty cash flow upside.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-05
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpoint”, revision 1, evidence through 2026-09-05. https://marketontology.com/catalysts/2026-09-05/novartis-phase-3-pelacarsen-cardiovascular-trial-misses-primary-endpoint-0bc179
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| RPRX | ▼Bear | 1–4 weeks | elimination of future pipeline royalty cash flow upside | 61 |
Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpoint
Phase 3 clinical trial failures eliminate projected royalty cash flows and downstream drug commercialization revenue for licensing partners. — bearish pressure on RPRX via elimination of future pipeline royalty cash flow upside.
Royalty Pharma announced Novartis Phase 3 HORIZON trial failed primary endpoint.
- SourceRoyalty Pharma announced Novartis Phase 3 HORIZON trial failed primary endpoint.
- TransmissionPhase 3 clinical trial failures eliminate projected royalty cash flows and downstream drug commercialization revenue for licensing partners.
- SummaryNovartis' Phase 3 HORIZON cardiovascular trial for pelacarsen failed primary endpoint. Royalty Pharma expects to recover its $500M invested capital despite the trial miss. Outcome dims near-term commercialization prospects for Lp(a) cardiovascular treatments.
- RPRXDirect directional or hedged short
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Fed officials or competing data may reframe the print
- RPRX closes above pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- RPRX price vs. pre-event level
- RPRX volume vs. 20-day average
- 2Y/10Y Treasury yield direction
- DXY direction
- Fed funds futures repricing
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen · POLYGON NEWS · 2026-09-04
Related catalysts
- 2026-09-05Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500MNVS RPRX
- 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular EndpointIONS NVS RPRX-11.45%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.